• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Humoral and T cell Responses to SARS-CoV-2 Vaccine Booster and Anti-SARS-CoV-2 Monoclonal Antibodies in Patients With End-Stage Kidney Disease.

作者信息

Zaza Gianluigi, Stallone Giovanni, Granata Simona, Gentile Micaela, Panico Maddalena, Bin Sofia, Wang Lin, Rollenhagen Christiane, Maltzman Jonathan S, Cravedi Paolo

机构信息

Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出版信息

Kidney Int Rep. 2023 Apr 29;8(7):1473-5. doi: 10.1016/j.ekir.2023.04.026.

DOI:10.1016/j.ekir.2023.04.026
PMID:37360818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10148717/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ef/10334386/f3450a622811/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ef/10334386/f3450a622811/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ef/10334386/f3450a622811/gr1.jpg

相似文献

1
Humoral and T cell Responses to SARS-CoV-2 Vaccine Booster and Anti-SARS-CoV-2 Monoclonal Antibodies in Patients With End-Stage Kidney Disease.终末期肾病患者对SARS-CoV-2疫苗加强针和抗SARS-CoV-2单克隆抗体的体液和T细胞反应
Kidney Int Rep. 2023 Apr 29;8(7):1473-5. doi: 10.1016/j.ekir.2023.04.026.
2
T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.养老院居民中初次接种和加强接种 SARS-CoV-2 信使 RNA 疫苗后的 T 细胞介导的反应。
J Am Med Dir Assoc. 2023 Feb;24(2):140-147.e2. doi: 10.1016/j.jamda.2022.11.024. Epub 2022 Dec 7.
3
The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans.mRNA新冠疫苗加强针在患癌退伍军人中对免疫反应的影响。
Med Res Arch. 2022 Jul 31;10(7). doi: 10.18103/mra.v10i7.2932.
4
Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.免疫抑制患者对 SARS-CoV-2 疫苗接种和加强针的细胞和体液免疫反应：一项观察性队列研究。
J Clin Virol. 2022 Aug;153:105217. doi: 10.1016/j.jcv.2022.105217. Epub 2022 Jun 11.
5
Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity.SARS-CoV-2 疫苗诱导的免疫反应在腹膜透析患者中持续 6 个月以上的情况，以及加强剂量在维持血清阳性中的作用。
Nephron. 2022;146(6):559-563. doi: 10.1159/000524658. Epub 2022 May 20.
6
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.在接受利妥昔单抗治疗的自身免疫性疾病患者中，第二次和第三次接种 SARS-CoV-2 疫苗后的细胞和体液反应：特异性 T 细胞免疫持续时间更长，并对 SARS-CoV-2 再感染起到保护作用。
Front Immunol. 2023 Apr 27;14:1146841. doi: 10.3389/fimmu.2023.1146841. eCollection 2023.
7
A Third Dose of SARS-CoV-2 mRNA Vaccine Improves Immune Response in Chronic Kidney Disease Patients.第三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗可改善慢性肾病患者的免疫反应。
Vaccines (Basel). 2023 May 22;11(5):1012. doi: 10.3390/vaccines11051012.
8
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.肠道炎症中 SARS-CoV-2 免疫的全身和 T 细胞相关反应（STAR SIGN 研究）：生物制剂对 mRNA 疫苗第三剂预防 SARS-CoV-2 效果的影响。
Aliment Pharmacol Ther. 2023 Jan;57(1):103-116. doi: 10.1111/apt.17264. Epub 2022 Oct 28.
9
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.免疫应答：SARS-CoV-2 mRNA 疫苗接种和加强剂在多发性骨髓瘤和单克隆丙种球蛋白病患者中的作用：Omicron 变异对体液免疫应答的影响。
Oncoimmunology. 2022 Sep 6;11(1):2120275. doi: 10.1080/2162402X.2022.2120275. eCollection 2022.
10
Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.SpikoGen 的免疫原性和安全性，SpikoGen 是一种含佐剂的重组 SARS-CoV-2 刺突蛋白，作为肾移植患者的异源第三剂加强针：一项单臂临床试验。
Clin Ther. 2022 Dec;44(12):1566-1576. doi: 10.1016/j.clinthera.2022.10.002. Epub 2022 Oct 24.

本文引用的文献

1
Antibody Responses Against Emerging SARS-CoV-2 Omicron Lineages After the Fourth Dose of mRNA Vaccine in Kidney Transplant Recipients.肾移植受者接种第四剂mRNA疫苗后针对新出现的SARS-CoV-2奥密克戎谱系的抗体反应
Transplantation. 2023 Jun 1;107(6):e178-e181. doi: 10.1097/TP.0000000000004582. Epub 2023 May 23.
2
Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose.肾移植受者接种第三剂 mRNA 疫苗后持续存在的 SARS-CoV-2 特异性免疫缺陷。
Am J Transplant. 2023 Jun;23(6):744-758. doi: 10.1016/j.ajt.2023.03.014. Epub 2023 Mar 24.
3
Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis.
二价mRNA加强针在接受血液透析患者中的免疫效果
N Engl J Med. 2023 Mar 9;388(10):950-952. doi: 10.1056/NEJMc2216309. Epub 2023 Feb 15.
4
Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients.肾移植受者中新冠疫情第一波和第二波期间死亡率无差异
Kidney Int Rep. 2022 Dec;7(12):2617-2629. doi: 10.1016/j.ekir.2022.09.007. Epub 2022 Sep 21.
5
The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients Calls for Further Action.肾移植受者中较高的新冠病毒病死亡率需要采取进一步行动。
Transplantation. 2022 May 1;106(5):908-910. doi: 10.1097/TP.0000000000004086. Epub 2022 Mar 3.